TY - JOUR
T1 - The Kinase Specificity of Protein Kinase Inhibitor Peptide
AU - Chen, Yao
AU - Sabatini, Bernardo L.
N1 - Funding Information:
This work was supported by grants from the Brain & Behavior Research Foundation (NARSAD Young Investigator Grant 28323 to YC), a Goldenson Fund postdoctoral fellowship (to YC) and NINDS (R37NS046579, to BS).
Publisher Copyright:
© Copyright © 2021 Chen and Sabatini.
PY - 2021/1/29
Y1 - 2021/1/29
N2 - G-protein-coupled-receptor (GPCR) signaling is exquisitely controlled to achieve spatial and temporal specificity. The endogenous protein kinase inhibitor peptide (PKI) confines the spatial and temporal spread of the activity of protein kinase A (PKA), which integrates inputs from three major types of GPCRs. Despite its wide usage as a pharmaceutical inhibitor of PKA, it was unclear whether PKI only inhibits PKA activity. Here, the effects of PKI on 55 mouse kinases were tested in in vitro assays. We found that in addition to inhibiting PKA activity, both PKI (6–22) amide and full-length PKIα facilitated the activation of multiple isoforms of protein kinase C (PKC), albeit at much higher concentrations than necessary to inhibit PKA. Thus, our results call for appropriate interpretation of experimental results using PKI as a pharmaceutical agent. Furthermore, our study lays the foundation to explore the potential functions of PKI in regulating PKC activity and in coordinating PKC and PKA activities.
AB - G-protein-coupled-receptor (GPCR) signaling is exquisitely controlled to achieve spatial and temporal specificity. The endogenous protein kinase inhibitor peptide (PKI) confines the spatial and temporal spread of the activity of protein kinase A (PKA), which integrates inputs from three major types of GPCRs. Despite its wide usage as a pharmaceutical inhibitor of PKA, it was unclear whether PKI only inhibits PKA activity. Here, the effects of PKI on 55 mouse kinases were tested in in vitro assays. We found that in addition to inhibiting PKA activity, both PKI (6–22) amide and full-length PKIα facilitated the activation of multiple isoforms of protein kinase C (PKC), albeit at much higher concentrations than necessary to inhibit PKA. Thus, our results call for appropriate interpretation of experimental results using PKI as a pharmaceutical agent. Furthermore, our study lays the foundation to explore the potential functions of PKI in regulating PKC activity and in coordinating PKC and PKA activities.
KW - endogenous
KW - facilitation
KW - inhibition
KW - kinase screen
KW - protein kinase A
KW - protein kinase C
KW - protein kinase inhibitor peptide
KW - specificity
UR - http://www.scopus.com/inward/record.url?scp=85101045474&partnerID=8YFLogxK
U2 - 10.3389/fphar.2021.632815
DO - 10.3389/fphar.2021.632815
M3 - Article
C2 - 33584320
AN - SCOPUS:85101045474
SN - 1663-9812
VL - 12
JO - Frontiers in Pharmacology
JF - Frontiers in Pharmacology
M1 - 632815
ER -